Main Services:
Main Product of Armed-T Cell Technology
▪ The lead Armed-T cell product, CTA-02, is for treating colorectal cancer (CRC) with EGFR downstream (Kras, Braf, and Nras) mutations (present in approximately 50% of untreatable CRC patients). ▪ Preclinical data have shown that CTA-02 is highly tumor-specific and effective in reducing the tumor burden of CRC tumors. No signs of cytokine release syndrome and other toxicities were observed. ▪ CTA-02 is ready to initiate clinical trials for untreatable CRC in the US, Singapore, and Taiwan in 2024.
Pipelines of Other Armed-T cell products:
▪ CTA-01 for B-cell leukemia and CTA-06 for recurrent/refractory solid tumors have been sublicensed to expedite their entry into clinical trials in 2024. ▪ CTA-03 for prostate tumor and CTA-04 for metastatic breast tumor are under development in the CMC stage. ▪ Over 50 products are protected by worldwide patents.
Business Interests
▪ Out-Licensing of Armed-T cell Technology and Products ▪ Clinical Trial Collaboration ▪ Fundraising
Contact Info
Ting-Yu (Michael) Chen
VP
+886-930659571
tingyu.chen@cytoarm.com